CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

RECOMBINANT RESPIRATORY SYNCYTIAL VIRUS VACCINE (SYS6057) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

The Board of Directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the recombinant respiratory syncytial virus ("**RSV**") vaccine (SYS6057) (the "**Product**"), a Class 1 new preventive biological product developed by the Group, has been approved by the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the U.S. Furthermore, the Product obtained approval from the National Medical Products Administration of the PRC (NMPA) on 30 July 2026 to conduct clinical trials.

The Product is the Group's second recombinant protein vaccine product to receive approval to conduct clinical trials. It comprises the prefusion F (Pre-F) protein antigen of respiratory syncytial virus and the Group's independently developed second-generation nano-adjuvant system. Compared with the previous product, the adjuvant of the Product employs a different nanocarrier, exhibiting unique physicochemical properties and immunological activity. Through optimisation of this adjuvant system, the Product can simultaneously induce high-titre neutralising antibodies and potent cellular immune responses against RSV, possessing distinctive advantages in immune protection. Preclinical studies demonstrated that the Product exhibited a favourable safety and efficacy profile.

The clinical indication approved for this clinical trial is for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals aged 60 years and above. The clinical trial approval of the Product lays a solid foundation for the Group's subsequent development of recombinant protein vaccines and adjuvant products, marking the official entry of the Group's vaccine research and development pipeline into a new stage of rapid development.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 25 August 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.